(CLMT) Calumet Specialty Products - Overview
Stock: Solvents, Waxes, Lubricants, Renewable Diesel, Aviation Fuel
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 33.1% |
| Relative Tail Risk | -11.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.97 |
| Alpha | 30.59 |
| Character TTM | |
|---|---|
| Beta | 1.446 |
| Beta Downside | 2.412 |
| Drawdowns 3y | |
|---|---|
| Max DD | 61.87% |
| CAGR/Max DD | 0.20 |
Description: CLMT Calumet Specialty Products January 15, 2026
Calumet Specialty Products Partners (NASDAQ: CLMT) is a century-old refiners’ and specialty chemicals company that produces branded specialty chemicals and renewable fuels for North American and international markets.
The business is organized into three segments: Specialty Products & Solutions (solvents, waxes, custom lubricants, white oils, gels, esters, etc.), Montana/Renewables (renewable diesel, sustainable aviation fuel, renewable hydrogen, renewable natural gas, propane, naphtha, plus conventional fuels from Canadian crude), and Performance Brands (high-performance aftermarket products sold under Royal Purple, Bel-Ray, and TruFuel). The company sells primarily through wholesale distributors and retail chains.
Key recent data points: Q4 2023 revenue was $2.1 billion, with adjusted EBITDA margin of ~14%; the Montana/Renewables segment now runs ~300 k bpd of renewable-fuel capacity, positioning it to capture growth from the U.S. Renewable Fuel Standard and the emerging Sustainable Aviation Fuel mandate. A primary sector driver is the accelerating policy-backed demand for low-carbon fuels, which is expected to raise renewable-fuel utilization rates by 6-8 percentage points annually through 2028.
For a deeper quantitative view, you might explore ValueRay’s analyst toolkit to model CLMT’s exposure to these renewable-fuel trends.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.03 > 0.02 and ΔFCF/TA -3.97 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.00 > 3% & CFO -11.0m > Net Income -69.0m |
| Net Debt (2.21b) to EBITDA (253.0m): 8.73 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.7m) vs 12m ago 1.38% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 163.5%; Δ -163.5% > 0%) |
| Interest Coverage Ratio: 0.26 > 6 (EBITDA TTM 253.0m / Interest Expense TTM 216.0m) |
Altman Z'' -1.95
| A: 0.04 (Total Current Assets 880.1m - Total Current Liabilities 776.3m) / Total Assets 2.73b |
| B: -0.56 (Retained Earnings -1.54b / Total Assets 2.73b) |
| C: 0.02 (EBIT TTM 57.0m / Avg Total Assets 2.69b) |
| D: -0.48 (Book Value of Equity -1.53b / Total Liabilities 3.18b) |
| Altman-Z'' Score: -1.95 = D |
What is the price of CLMT shares?
Over the past week, the price has changed by +12.41%, over one month by +28.59%, over three months by +29.11% and over the past year by +52.57%.
Is CLMT a buy, sell or hold?
- StrongBuy: 2
- Buy: 2
- Hold: 3
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CLMT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 22.7 | -10.1% |
| Analysts Target Price | 22.7 | -10.1% |
| ValueRay Target Price | 29.1 | 15.4% |
CLMT Fundamental Data Overview February 03, 2026
P/S = 0.4803
P/B = 19.3228
P/EG = 2.71
Revenue TTM = 0.0 USD
EBIT TTM = 57.0m USD
EBITDA TTM = 253.0m USD
Long Term Debt = 2.15b USD (from longTermDebt, last quarter)
Short Term Debt = 155.2m USD (from shortTermDebt, last quarter)
Debt = 2.30b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.21b USD (from netDebt column, last quarter)
Enterprise Value = 4.15b USD (1.94b + Debt 2.30b - CCE 94.6m)
Interest Coverage Ratio = 0.26 (Ebit TTM 57.0m / Interest Expense TTM 216.0m)
EV/FCF = -54.92x (Enterprise Value 4.15b / FCF TTM -75.6m)
FCF Yield = -1.82% (FCF TTM -75.6m / Enterprise Value 4.15b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 1.52 (Enterprise Value 4.15b / Total Assets 2.73b)
Interest Expense / Debt = 2.21% (Interest Expense 51.0m / Debt 2.30b)
Taxrate = 21.0% (US default 21%)
NOPAT = 45.0m (EBIT 57.0m * (1 - 21.00%))
Current Ratio = 1.13 (Total Current Assets 880.1m / Total Current Liabilities 776.3m)
Debt / Equity = -3.31 (negative equity) (Debt 2.30b / totalStockholderEquity, last quarter -695.3m)
Debt / EBITDA = 8.73 (Net Debt 2.21b / EBITDA 253.0m)
Debt / FCF = -29.21 (negative FCF - burning cash) (Net Debt 2.21b / FCF TTM -75.6m)
Total Stockholder Equity = -820.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.57% (Net Income -69.0m / Total Assets 2.73b)
RoE = 8.41% (negative equity) (Net Income TTM -69.0m / Total Stockholder Equity -820.0m)
RoCE = 4.29% (EBIT 57.0m / Capital Employed (Equity -820.0m + L.T.Debt 2.15b))
RoIC = 3.11% (NOPAT 45.0m / Invested Capital 1.45b)
WACC = 6.09% (E(1.94b)/V(4.25b) * Re(11.24%) + D(2.30b)/V(4.25b) * Rd(2.21%) * (1-Tc(0.21)))
Discount Rate = 11.24% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 4.00%
Fair Price DCF = unknown (Cash Flow -75.6m)
EPS Correlation: 7.76 | EPS CAGR: 28.81% | SUE: 0.16 | # QB: 0
Revenue Correlation: -42.92 | Revenue CAGR: -62.50% | SUE: 0.40 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.15 | Chg30d=-0.080 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.17 | Chg30d=-0.200 | Revisions Net=-1 | Growth EPS=+19.1% | Growth Revenue=+1.0%